The company currently has 22 projects in its portfolio for the…

The company currently has 22 projects in its portfolio for the development of original molecules and bioanalogues for the therapy of oncological, autoimmune, and neurodegenerative diseases.

Coverage (2 sources)

Key entities

More on Maxim Liksutov